



To study the efficacy of Heart Failure Reversal Therapy (HFRT) program in elderly male patients with reduced ejection fraction

Rohit Sane, Rahul Mandole*

Department of Research and Development, Madhavbaug Cardiac Care Clinics and Hospitals, Mumbai, Maharashtra, India

Abstract

Background and Aims: Some authors consider heart failure (HF) to be a pandemic now, since nearly 26 million people have been affected by it, globally. Out of these, India alone has around 8-10 million patients. Heart Failure Reversal Therapy (HFRT) combines Herbal *Panchakarma* therapy with Dietary management. This study was conducted to evaluate the effect of HFRT on VO₂peak, 6 Minute Walk Test (6MWT), systolic blood pressure (SBP), and diastolic blood pressure (DBP), BMI, weight, abdominal girth, and heart rate.

Setting and Design: This observational study was conducted from January 2015 to December 2017, wherein the data of elderly male patients with HF (NYHA class II and III) with reduced ejection fraction (<40%) who attended *Madhavbaug hospital, Khopoli, Maharashtra*, India were identified.

Materials and Methods: Data of patients who were administered HFRT (60-75 minutes) with minimum 7 sittings over 7 days were considered. Variables were compared between day 1, 7, 30, 60 and day 90 of HFRT.

Results: 50 elderly males with HF and EF < 40% were enrolled in the study for analysis. There was significant improvement in VO₂peak, from 12.71 ± 2.47 at baseline to 14.89 ± 2.05 at day 90 ($p < 0.001$). 6MWT also showed significant improvement from 339.42 ± 106.85 at day 1 to 432.4 ± 89.27 at day 90 ($p < 0.001$). Also, BMI, abdominal girth, weight showed similar statistically significant improvements. Improvements in SBP, DBP and HR were not statistically significant.

Conclusion: From the findings of our study, HFRT has been found to be a potent and viable therapeutic alternative for elderly male patients with HF with reduced ejection fraction.

Keywords: heart failure reversal therapy, HFRT, Panchakarma, heart failure, blood pressure, systolic, diastolic, VO₂peak, 6MWT, NYHA

1. Introduction

Reduced capacity of the heart to function optimally leading to insufficient amount of blood pumped for routine metabolic activities, resulting in increased resting pressure within the heart is known as Heart Failure (HF) [1, 2]. Some authors consider HF to be a pandemic now, since nearly 26 million people have been affected by it, globally. Out of these, India alone has around 8-10 million patients. Even the mortality rates in India due to HF are as high as 0.16 million per year [3]. In past few decades, urbanization and industrialization has boomed significantly in India, which has greatly contributed to increased sedentary lifestyle and other risk factors of HF. Due to improved healthcare, population in age group >60 years have escalated by more than 1.7 times in a short span of 20 years [4]. Since advancing age is a major risk factor for HF, it is logical to anticipate that prevalence and burden of HF in India is rising [5]. Apart from age, Hypertension (HTN) is other major risk factor for HF patient. Cases of HTN are consistently increasing with every passing year, thus increasing the likelihood of HF cases [6, 7].

A variety of drugs are available for treatment of HF, like angiotensin 2 receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEIs), beta blockers, diuretics, anti-platelet drugs, etc [8]. Despite availability of extensive list of conventional therapeutic options, HF carries poor prognosis. HF has dual effects on patients- firstly, direct

effect of its symptoms, and secondly anxiety and dread associated with these symptoms. These dual effects adversely affect quality of life of patient. Also, it has been commonly observed that adherence to conventional therapies is less than 50% in such patients, attributed to high cost of therapy, adverse effects of drugs, etc [9]. Due to these drawbacks of conventional therapies, there is need of novel therapy which will maintain and preserve optimal heart function and raise the quality of life of the patient [10].

Therapeutic benefits of conventional therapies in HF like ACEIs, ARBs, beta blockers, diuretics are due to anti-inflammatory, hypolipidemic, antiplatelet, and antioxidant actions [11]. Similar actions have been found in various herbal drugs in clinical studies [12, 13, 14]. Thus, the quest for search of novel therapeutic agent for the management of HF can end up here. *Panchakarma* and diet therapy are combined under the umbrella of Heart Failure Reversal Therapy (HFRT). *Panchakarma* in HFRT is administered via *Snehana* (External Oleation Therapy), *Swedana* (Passive Heat Treatment), *Hrudaydhara* (Decoction Drip Therapy), and *Basti* (Per Rectal administration); which are established detoxifying procedures [15, 16].

Functional working capacity is reduced in HF, as measured by maximum aerobic capacity/VO₂peak [17]. This reflects in reduced quality of life [18]. Keeping this in mind, we planned an observational study, to analyze the effect of HFRT on

VO₂peak in elderly male of HF with reduced ejection fraction (EF<40%). We also analyzed the effect of HFRT on SBP, DBP, HR, weight, BMI, abdominal girth.

2. Materials and methods

- Sample Size: 50
- Study design: Observational.
- Duration of study: January 2015 to December 2017
- Study Site: *Madhavbaug Hospital, Khopoli, Maharashtra, India.*
- Inclusion Criteria: We have observed the efficacy of HFRT program in:
 - Elderly male patients = Age \geq 60 years
 - Ejection fraction = \leq 40%
 - NHYA Grade – II and III
- Methodology
 - We identified the data of male patients suffering from

HF (New York Heart Association, NYHA Class II–III) of age >60 years, and who had attended the out-patient departments (OPDs) at *Madhavbaug hospital* located in *Khopoli, Maharashtra, India*. The data of patients who had been administered HFRT with minimum 7 sittings over a span of 7 days were considered for the study. Cases were identified, and data was assessed from the records of *Madhavbaug Hospital in Khopoli, Maharashtra*. The selection was based upon the availability of complete relevant baseline data (day 1 of HFRT) to final day data (day 90 of HFRT) of the patients. The information about comorbidities, if any, was also noted down.

- The Follow-up schedule is shown in figure 1.
- Primary End-point: VO₂peak
- Secondary End-points: Weight, BMI, Abdominal Girth, Heart Rate, SBP and DBP.




Fig 1: showing follow-up schedule.

The HFRT is a 4-step procedure, which was performed on the patients with HF after a light breakfast. One sitting of the

procedure took 65-75 minutes, as described in table 1 [16, 19].

Table 1: Study Treatment: Heart Failure Reversal Therapy (HFRT)

Step of HFRT	Type of Therapy	Herbs used for therapy	Duration of Therapy
<i>Snehana</i>	Massage or external oleation (centripetal upper strokes directed towards heart)	10 grams <i>T. arjuna</i> , 10 grams <i>Dashamoola</i> and 5 grams <i>V.negundo</i> [100 ml extract processed in sesame oil]	30-35 minutes
<i>Swedana</i>	Passive heat therapy	<i>Dashmoola</i> (group of ten herbal roots) with steam at \leq 40 degrees Celsius)	10-15 minutes + 3-4 minutes of relaxation after procedure
<i>Hrudaydhara</i>	Decoction dripping therapy from a height of 7-8 cm	Luke-warm <i>dashmoola</i> decoction	15 minutes
<i>Basti</i>	Drug administered per rectal, should be in body for \geq 15 minutes for maximum absorption	1.88 grams <i>T. arjuna</i> , 0.42 grams <i>B. diffusa</i> and 0.18 grams <i>A. calamus</i> [10 ml aqueous extract]	10 minutes

On day 1 of HFRT, the patients had undergone 6MWT, VO₂peak, SBP, DBP as per international recommendations [20]. These readings were considered as baseline readings. This process was repeated as per figure 1. The patients followed a diet chart/plan of 1000-1200 kcal/day.

Statistical analysis

Repeated measured ANOVA was used to test statistical significance for Primary endpoint (Improvement in VO₂peak) and secondary endpoint (reduction in Weight, BMI, abdominal Girth, Heart Rate, SBP and DBP as well as

reduction in dependency of conventional medicine) for a washout period (DoA, DoD, 1st follow up, 2nd Follow up and

3rd Follow up). We used R (Version 3.5.0) software and excel to analyze the data (table 2).

Table 2: Hypothesis for ANOVA test

Null Hypothesis	Means are equal among all 5 different time periods i.e. DOA, DOD, 1 f/u, 2 f/u & 3 f/u
Alternative Hypothesis	Means of at least 2 groups are significantly different
Level of significance	0.05

3. Results

3.1 Study population

A total of 55 patients' data was screened for inclusion in the study. However, based on the availability of data (Day 1, day 7, day 30, 60 and Day 90) and the inclusion criteria, 50 patients were selected, and their data were considered for analysis. The baseline characteristics of these patients are

shown in table 3.

Demographic characteristics of the subjects enrolled in the study was as shown in Table 2. The present involved a total of 50 HF patients. The mean age of the enrolled subjects was 67.84 ± 5.71 years. The mean ejection fraction in these patients was 30.78 ± 5.54 .

Table 3: Baseline characteristics of the study subjects (n= 30)

Variable	Mean \pm SD
Gender (M)	50/0
Age (Years)	67.84 ± 5.71
Height (cm)	165.45 ± 5.93
LV Mass	241.22 ± 61.08
EF	30.78 ± 5.54
Past medical history Frequency (%)	
CAD	24 (48.00)
HTN	31 (62.00)
DM	21 (42.00)
IHD	33 (66.00)
MI	6 (12.00)
NYHA functional class Frequency (%)	
Class I	0 (0.00)
Class II	34 (68.00)
Class III	13 (26.00)
Class IV	1 (2.00)

Data were expressed in % and mean \pm SD

The baseline characteristics of the study populations are shown in Table 3. In that 50 subjects, 24 (48%) have Coronary artery disease (CAD), 31 (62%) have Hypertension (HTN), 21 (42%) have Diabetic Mellitus (DM), 33 (66%) have ischemic

heart disease (IHD), 6 (12%) have Myocardial infarction (MI). Most of the patients belongs Class II 34 (68%) and Class III 13 (26%) as per NYHA functional class. Only single respondent belongs to class IV.

Table 4: Effect of HFRT treatment on improvement of various body parameters according to overall and NYHA subjects

Variable	Sample size	Mean \pm SD					P-value	Conclusions from ANOVA
		DOA	DOD	1 f/u	2 f/u	3 f/u		
VO2 Peak	50	12.71 ± 2.47	13.96 ± 2.12	14.65 ± 2.15	14.8 ± 2.19	14.89 ± 2.05	<0.001	Statistically significant
6 MWT (Meters)	50	339.42 ± 106.85	391.98 ± 91.97	422 ± 93.5	428.2 ± 95.08	432.4 ± 89.27	<0.001	Statistically significant
Weight	50	64.82 ± 12.01	62.91 ± 11.67	62.31 ± 11.26	62.37 ± 10.89	62.48 ± 10.94	<0.001	Statistically significant
BMI	50	23.56 ± 3.92	22.85 ± 3.73	22.64 ± 3.6	22.66 ± 3.47	22.7 ± 3.47	<0.001	Statistically significant
Abdominal Girth	50	91.66 ± 10.4	89.82 ± 10.19	89.16 ± 9.94	88.2 ± 9.47	89.04 ± 9.43	<0.001	Statistically significant
Heart Rate	50	76.5 ± 12.77	78.3 ± 11.42	72.94 ± 13.41	74.82 ± 13.18	75.54 ± 11.96	0.14	Statistically insignificant
SBP	50	114.04 ± 14.57	115.2 ± 14.18	112.8 ± 15.52	112.32 ± 12.86	115.6 ± 14.02	0.49	Statistically insignificant
DBP	50	73.6 ± 8.75	74 ± 8.08	72.4 ± 8.47	73.32 ± 10.77	72.8 ± 8.34	0.79	Statistically insignificant

Effect of HFRT treatment on improvement of body parameter is summarized in Table 4. For all 50 cases, HFRT treatment showed significant improvement in weight, BMI, Abdominal Girth, 6MWT (meters) and VO2peak. HFRT treatment wasn't

statistically significant for Heart rate, SBP and DBP.

Following figure shows us a comparison of endpoint among all time periods (DoA, DoD, 1st follow up, 2nd Follow up and 3rd Follow up).

Fig 2.1: Comparison of VO2 Peak




Fig 2.2: Comparison of 6MWT




Fig 2.3: Comparison of Weight





Fig 2.4: Comparison of BMI



Charts generated on : 2018-06-19 00:01:06

Fig 2.5: Comparison of Abdominal Girth




Fig 2.6: Comparison of Heart Rate




Fig 2.7: Comparison of SBP





Fig 2.8: Comparison of DBP



Charts generated on : 2018-06-18 21:53:19

Fig 2: showing effect of HFRT on body parameters

Thus, HFRT treatment showed statistically significant results for the primary endpoint (Improvement in VO2peak) but partially significant in case of secondary endpoint (Reduction in Weight, BMI, abdominal Girth, Heart Rate, SBP and DBP). Heart rate, SBP and DBP were statistically insignificant amongst secondary endpoint.

4. Discussion

The present observational study analyzed the effect of HFRT in elderly males of HF, found that there was significant improvement in 6MWT and VO2peak from day1 to day 7 of HFRT. It was fascinating to observe that these improvements were sustained even on day 90 of follow-up. Even secondary

endpoints like BMI, weight, abdominal girth showed substantial improvement after HFRT. Oxygen uptake is drastically reduced in patients of HF due to weakened heart. This is reflected by reducing VO₂peak^[21]. Thus, significant improvement in VO₂peak in the present study carries a favourable prognosis in patients with HF. This was corroborated by the findings of other such studies, although treatments used in those studies were different^[22]. Around 14-16% reduction in risk of mortality with increase in VO₂peak by 1ml/kg/min was seen in one clinical study in patients with ischemic heart disease^[23]. Thus, significant improvement in VO₂peak in the present study signifies favourable prognosis in patients of HF. VO₂peak increased in the present study by hefty margin of around 50% from baseline to day 90 of follow-up. This indicates a reduction in death risk in patients with HF.

Despite availability of wide range of conventional allopathic drugs and extensively designed guidelines to combat the havoc of HF, morbidity and mortality of HF is rising continuously. *Panchakarma* is administered in HFRT as 4-step process, which includes *Snehana*, *Swedana*, *Hrudaydhara* and *Basti*^[24]. Plausible mechanism of HFRT might be:

1. *Snehana*- calms the patient through its anxiolytic effect
2. *Swedana*- reduces preload of the heart by reducing water and sodium load
3. *Hrudaydhara*- which is a type of *Shirodhara*; it calms the patient and helps in reduction of BP
4. *Basti*- *Terminalia arjuna* helps in reduction of BP, thus reducing afterload of heart [*terminalia*].

We studied the effect of HFRT in elderly male of HF with reduced EF and found significant improvement in VO₂peak and 6MWT at the end of 3rd follow-up visit. Since the patients had EF < 40%, stress test was contraindicated. VO₂peak is reduced in patients with HF due to the reduced pumping action of heart^[25]. Reduced VO₂peak in HF patients clinically as diminished capacity to work/exercise^[26]. VO₂peak is derived from Cahalin's formula, using the results of 6MWT, as stated below^[25].

$$\text{Mean Peak VO ml/kg/min} = 4.948 + 0.023 \times \text{Mean 6 MWD (meters)}$$

Where: 6MWD is 6 minute walk distance measured by 6 minute walk test (6MWT).

A 6MWT result >300 meter and VO₂peak >12 has been found to be associated with better survival long term, in patients with HF^[27]. In the present study we found that, both 6MWT was more than 400 meters and VO₂peak more than 14 points, which signifies better prognosis, thus reducing risk of mortality in patients of HF. Increased BMI, and abdominal girth are associated with increased morbidity and mortality in HF patients. Significant reduction in BMI and abdominal girth after 90th day of HFRT, indicates favorable prognosis in terms of reduction of risk of mortality in patients of HF.^[28] Although, significant positive findings were obtained in the present study, further such studies need to be done on a larger scale, probably a prospective head to head comparative clinical trial, so as to generalize the findings of present study to larger population.

6. Conclusions

We observed significant improvement in VO₂peak, 6MWT coupled with reduction in body weight, BMI; HFRT offers a promising candidature for consideration as potent therapeutic option for treatment of elderly males of HF with reduced EF.

7. Acknowledgments

Author thanks to Dr Jagdish Hiremath, Chair Professor of Madhavbaug Institute of Preventive Cardiology, Chair of Maharashtra University of Health Science, Nashik for guiding us through this concept and data analysis.

8. References

1. Coronel R, de Groot J, Van Lieshout J. Defining heart failure. *Cardiovasc Res*. 2001; 50:419-22.
2. Tan L, Williams S, Tan D, *et al*. So many definitions of heart failure: are they all universally valid? A critical appraisal. *Expert Rev Cardiovasc Ther*. 2010; 8:217-28.
3. Chaturvedi V, Parakh N, Seth S, *et al*. Heart failure in India: The INDUS (INDia Ukieri Study) study. *J Pract Cardiovasc Sci*. 2016; 2:28-35.
4. National Commission on Population, Government of India. Available at <http://populationcommission.nic.in/> [Last accessed on 31st May 2018].
5. Lloyd-Jones D, Larson M, Leip E, *et al*. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. *Circulation*. 2002; 106:3068-72.
6. Hansson L, Zanchetti A, Carruthers S, *et al*. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. *Lancet*. 1998; 351:1755-62.
7. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials. *Lancet*. 2000; 356:1955-64.
8. Yancy C, Jessup M, Bozkurt B, *et al*. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013; 62(16):e147-e239.
9. Kolandaivelu K, Leiden R, O'Gara P, *et al*. Non-adherence to cardiovascular medications. *European Heart Journal*. 2014; 35:3267-3276.
10. Asadi-Lari M, Rao A, Gray D. Health-related quality-of-life tools in heart failure. *Expert Rev Pharmacoecon Outcomes Res*. 2005; 5(3):267-270.
11. Dandona P, Ghanim H, Brook D. Antioxidant activity of carvedilol in cardiovascular disease. *J Hypertens*. 2007; 25:731-741.
12. Verma S, Bordia A. Effect of *Terminalia arjuna* bark (arjun chhal) in patients of congestive heart failure and hypertension. *J Res Educ Indian Med*. 1988; 7:31-36.
13. Pereira D, Faria J, Gaspar L, *et al*. Boerhaavia diffusa: metabolite profiling of a medicinal plant from

- Nyctaginaceae. Food Chem Toxicol. 2009; 47(8):2142-2149.
14. Parab R, Mengi S. Hypolipidemic activity of *Acorus calamus* L. in rats. Fitoterapia. 2002; 73(6):451-455.
15. Mishra L, ed. In: Scientific basis for ayurvedic therapies, September. CRC Press, 2003.
16. Uebaba K, Xu F, Ogawa H, *et al.* Psychoneuroimmunologic effects of Ayurvedic oildripping treatment. J Altern Complement Med. 2008; 14:1189-1198.
17. Ciolac E, Bocchi E, Silva M, *et al.* Effects of age on aerobic capacity in heart failure patients under beta-blocker therapy: Possible impact in clinical decision-making? Cardiology Journal. 2013; 20(6):655-6.
18. Arena R, Cahalin L, Borghi-Silva A, *et al.* Improving functional capacity in heart failure. Current Opinion in Cardiology. 2014; 29(5):467-74.
19. Taghadosi M, Arani Z, Gilani H. Quality of life in patients with ischemic heart disease. Journal of Nursing and Midwifery Sciences. 2014; 1(1):19-26.
20. Lairikyengbam S, Davies A. Interpreting exercise treadmill tests needs scoring system. BMJ. 2002; 325(7361):443.
21. Kemps H, De Vries W, Hoogeveen A, *et al.* Reproducibility of onset and recovery oxygen uptake kinetics in moderately impaired patients with chronic heart failure. Eur J Appl Physiol. 2007; 100(1):45-52.
22. Piepoli M, Davos C, Francis D, *et al.* ExTraMATCH Collaborative.Exercise training meta-analysis of trials in patients with chronic heart failure (ExTra- MATCH). BMJ. 2004; 328(7433):189.
23. Keteyian S, Brawner C, Savage P, *et al.* Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J. 2008; 156(2):292-300.
24. Sane R, Aklujkar A, Patil A, *et al.* Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. Indian Heart Journal. 2017; 69(3):299-304.
25. Cahalin L, Mathier M, Semigran M *et al.* The Six-Minute Walk Test Predicts Peak Oxygen Uptake and Survival in Patients With Advanced Heart Failure. CHEST. 1996; 110:325-32.
26. Rosendorf C, Lackland D, Allison M, *et al.* Treatment of Hypertension in Patients With Coronary Artery Disease. A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015; 65:1372-1407.
27. Ross R, Murthy J, Wollak I, *et al.* The sixtminute walk test accurately estimates mean peak oxygen uptake. BMC Pulmonary Medicine. 2010; 10(31):1-9.
28. Aune D, Sen A, Norat T, *et al.* Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality. A Systematic Review and Dose–Response Meta-Analysis of Prospective Studies. Circulation. 2016; 133:639-649.